In survivors, we observed a gradual reduction in the number of CD16-CD56+/++ subtypes, especially from the first to the second moment (acute phase of the viral disease); in non-survivors, these cell subtypes plateaued, with a slight increase in the third moment. This evidence concerns the gene NCAM1 and viral infectious disease.